Abstract:Clear cell renal cell carcinoma (ccRCC) is characterized by metabolic dysregulation and distinct immunological signatures. The interplay between metabolic and immune processes in the tumor microenvironment (TME) causes the complexity and heterogeneity of immunotherapy responses observed during ccRCC treatment. Herein, we initially identified two distinct metabolic subtypes (C1 and C2 subtypes) and immune subtypes (I1 and I2 subtypes) based on the occurrence of differentially expressed metabolism-related prognostic genes and immune-related components. Notably, we observed that immune regulators with upregulated expression actively participated in multiple metabolic pathways. Therefore, we further delineated four immunometabolism-based ccRCC subtypes (M1, M2, M3, and M4 subtypes) according to the results of the above classification. Generally, we found that high metabolic activity could suppress immune infiltration. Immunometabolism subtype classification was associated with immunotherapy response, with patients possessing the immune-inflamed, metabolic-desert subtype (M3 subtype) that benefits the most from immunotherapy. Moreover, differences in the shifts in the immunometabolism subtype after immunotherapy were observed in the responder and non-responder groups, with patients from the responder group transferring to subtypes with immune-inflamed characteristics and less active metabolic activity (M3 or M4 subtype). Immunometabolism subtypes could also serve as biomarkers for predicting immunotherapy response. To decipher the genomic and epigenomic features of the four subtypes, we analyzed multiomics data, including miRNA expression, DNA methylation status, copy number variations occurrence, and somatic mutation profiles. Patients with the M2 subtype possessed the highest VHL gene mutation rates and were more likely to be sensitive to sunitinib therapy. Moreover, we developed non-invasive radiomic models to reveal the status of immune activity and metabolism. In addition, we constructed a radiomic prognostic score (PRS) for predicting ccRCC survival based on the seven radiomic features. PRS was further demonstrated to be closely linked to immunometabolism subtype classification, immune score, and tumor mutation burden. The prognostic value of the PRS and the association of the PRS with immune activity and metabolism were validated in our cohort. Overall, our study established four immunometabolism subtypes, thereby revealing the crosstalk between immune and metabolic activities and providing new insights into personal therapy selection.

Metabolic Classifications of Renal Cell Carcinoma Reveal Intrinsic Connections with Clinical and Immune Characteristics.

Metabolism-Related Signature Analysis Uncovers the Prognostic and Immunotherapeutic Characteristics of Renal Cell Carcinoma

A cluster of metabolism-related genes predict prognosis and progression of clear cell renal cell carcinoma

Prognostic Prediction and Immunotherapy Response Analysis of the Fatty Acid Metabolism-Related Genes in Clear Cell Renal Cell Carcinoma

Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes with Therapeutic Implications in Clear Cell Renal Cell Carcinoma.

The Identification of the Metabolism Subtypes of Skin Cutaneous Melanoma Associated with the Tumor Microenvironment and the Immunotherapy

Comprehensive Characterization of Metabolism-Associated Subtypes of Renal Cell Carcinoma to Aid Clinical Therapy.

Prognostic model for clear-cell renal cell carcinoma based on natural killer cell-related genes.

Identification of an amino acid metabolism-associated gene signature predicting the prognosis and immune therapy response of clear cell renal cell carcinoma

Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma

Metabolic Reprogramming of Cancer Stem Cells and a Novel Eight-Gene Metabolism-Related Risk Signature in Clear Cell Renal Carcinoma

Hybrid Metabolic Activity-Related Prognostic Model and Its Effect on Tumor in Renal Cell Carcinoma

Development and Validation of a Combined Hypoxia- and Metabolism-Related Prognostic Signature to Predict Clinical Prognosis and Immunotherapy Responses in Clear Cell Renal Cell Carcinoma

A novel amino acid metabolism-related gene risk signature for predicting prognosis in clear cell renal cell carcinoma

Mitochondrial Metabolic Reprogramming-Mediated Immunogenic Cell Death Reveals Immune and Prognostic Features of Clear Cell Renal Cell Carcinoma.

Prognostic impact of lactylation‐associated gene modifications in clear cell renal cell carcinoma: Insights into molecular landscape and therapeutic opportunities

Identification of an Metabolic Related Risk Signature Predicts Prognosis in Cervical Cancer and Correlates with Immune Infiltration

Comprehensive analysis of RNA sequencing and integrated machine learning reveals a metabolism related prognostic signature for improving outcomes in ccRCC

Adipogenic Transdifferentiation and Regulatory Factors Promote the Progression and the Immunotherapy Response of Renal Cell Carcinoma: Insights From Integrative Analysis

Metabolism-Relevant Molecular Classification Identifies Tumor Immune Microenvironment Characterization and Immunotherapeutic Effect in Cervical Cancer

A Fatty Acid Metabolism Signature Associated with Clinical Therapy in Clear Cell Renal Cell Carcinoma